标题
Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 23, Issue 3, Pages 791-800
出版商
Oxford University Press (OUP)
发表日期
2011-06-11
DOI
10.1093/annonc/mdr294
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Vulnerability of the Heart As a Pluricellular Paracrine Organ
- (2010) Gilles W. De Keulenaer et al. CIRCULATION RESEARCH
- Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial
- (2010) Marion Procter et al. JOURNAL OF CLINICAL ONCOLOGY
- Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials
- (2010) Stuart D. Russell et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
- (2010) Daniela Cardinale et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
- (2010) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline-Induced Cardiomyopathy
- (2010) Daniela Cardinale et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
- (2009) A L Jones et al. BRITISH JOURNAL OF CANCER
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes
- (2009) Laura Pentassuglia et al. EXPERIMENTAL CELL RESEARCH
- Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
- (2009) Edith A. Perez et al. MAYO CLINIC PROCEEDINGS
- Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?
- (2009) Evandro de Azambuja et al. Targeted Oncology
- Cardiac Toxicity of ErbB2-Targeted Therapies: What Do We Know?
- (2008) Edith A. Perez Clinical Breast Cancer
- A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
- (2008) J. Albanell et al. CLINICAL CANCER RESEARCH
- Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
- (2008) C. C. Portera et al. CLINICAL CANCER RESEARCH
- Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
- (2008) John Mackey Current Oncology
- Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
- (2008) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Cardiotoxicity: From Bench to Bedside
- (2008) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now